Heron Therapeutics, Inc. (HRTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on June 2, 2026, by Heron Therapeutics, Inc., a Delaware corporation. The report addresses a significant legal development regarding the company's patent portfolio for its product CINVANTI (aprepitant) injectable emulsion.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a material legal event and does not contain financial statement data.
Material Changes and Legal Developments
The primary event reported is a U.S. District Court for the District of Delaware decision issued on June 1, 2026, regarding patent infringement litigation against Slayback Pharma LLC (now owned by Azurity Pharmaceuticals, Inc.).
- Court Ruling: The Court held that the asserted claims of Heron's U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid.
- Impact on Settlements: The decision has no impact on any prior settlement agreements related to CINVANTI or APONVIE (aprepitant) injectable emulsion.
- Procedural History: The litigation began with a Paragraph IV notice in December 2023, followed by a bench trial in November 2025 and closing arguments in March 2026.
Outlook, Management Commentary, and Risks
Management intends to appeal the District Court's decision to the United States Court of Appeals for the Federal Circuit. The filing includes standard forward-looking statements regarding the appeal process and the ability to obtain a stay of market entry for the generic product. The company notes that actual results could differ materially due to risks outlined in its most recent Form 10-K and Form 10-Q filings.
Key Facts for Investor Verification
- Verify the specific scope of the invalidated patent claims (U.S. Patent Nos. 12,115,255 and 12,290,520) and their remaining coverage for CINVANTI.
- Confirm the timeline and status of the appeal filed with the Federal Circuit.
- Assess the potential for a stay of market entry for Azurity's generic version of CINVANTI pending the appeal.
- Review the company's most recent Form 10-K for updated risk factors related to intellectual property litigation.